Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med 2009 Jun;11(6):375-85 PMID: 19533842

Pubmed ID





Osteogenesis imperfecta is a systemic heritable disorder of connective tissue whose cardinal manifestation is bone fragility. In approximately 90% of individuals with osteogenesis imperfecta, mutations in either of the genes encoding the pro-alpha1 or pro-alpha2 chains of type I collagen (COL1A1 or COL1A2) can be identified. Of those without collagen mutations, a number of them will have mutations involving the enzyme complex responsible for posttranslational hydroxylation of the position 3 proline residue of COL1A1. Two of the genes encoding proteins involved in that enzyme complex, LEPRE1 and cartilage-associated protein, when mutated have been shown to cause autosomal recessive osteogenesis imperfecta, which has a moderate to severe clinical phenotype, often indistinguishable from osteogenesis imperfecta types II or III. Mutations in COL1A1 or COL1A2 which result in an abnormal protein still capable of forming a triple helix cause a more severe phenotype than mutations that lead to decreased collagen production as a result of the dominant negative effect mediated by continuous protein turnover. The current standard of care includes a multidisciplinary approach with surgical intervention when necessary, proactive physiotherapy, and consideration for the use of bisphosphonates all in attempts to improve quality of life.

Author List

Basel D, Steiner RD


Donald Basel MD Chief, Associate Professor in the Pediatrics department at Medical College of Wisconsin


2-s2.0-69549096354   84 Citations

MESH terms used to index this publication - Major topics in bold

Collagen Type I
Models, Biological
Osteogenesis Imperfecta
jenkins-FCD Prod-332 f92a19b0ec5e8e1eff783fac390ec127e367c2b5